Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre C Kalil

Showing results (61-70 of 277) with videos related to

Pageof 28
Sort By:
Annals of Internal Medicine|December 2, 2024
In persons exposed to influenza, zanamivir, oseltamivir, laninamivir, and baloxavir reduce symptomatic seasonal influenzaSias J Scherger, Andre C Kalil
The Lancet. Infectious Diseases|December 24, 2019
The last breath for inhaled antibiotics and VAP? Not so fastDaniel A Sweeney, Andre C Kalil
Critical Care Medicine|November 20, 2021
Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?Andre C Kalil, Kelly A Cawcutt
Chest|August 10, 2019
Quick Sequential Organ Failure Assessment Is Not Good for Ruling Sepsis In or OutAndre C Kalil, Flavia R Machado
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 5, 2021
Mortality in solid organ transplant recipients hospitalized for COVID-19Andre C Kalil, Diana F Florescu
Critical Care Medicine|May 25, 2022
From Syphilis to Sepsis: Pilot Studies and the Importance of Staying GroundedDaniel A Sweeney, Andre C Kalil
The Lancet. Infectious Diseases|September 30, 2019
Can ceftolozane-tazobactam treat nosocomial pneumonia?Andre C Kalil, Alexandre P Zavascki
Critical Care (London, England)|December 7, 2018
Didn't inhale? Time to reconsider aerosolized antibiotics in the treatment of ventilator-associated pneumoniaDaniel A Sweeney, Andre C Kalil
Virulence|November 21, 2013
The complex link between influenza and severe sepsisDiana F Florescu, Andre C Kalil
Critical Care (London, England)|July 6, 2013
Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysisAndre C Kalil, Diana F Florescu
Pageof 28

Showing results (61-70 of 277) with videos related to

Sort By:
Pageof 28
Annals of Internal Medicine|December 2, 2024
In persons exposed to influenza, zanamivir, oseltamivir, laninamivir, and baloxavir reduce symptomatic seasonal influenzaSias J Scherger, Andre C Kalil
The Lancet. Infectious Diseases|December 24, 2019
The last breath for inhaled antibiotics and VAP? Not so fastDaniel A Sweeney, Andre C Kalil
Critical Care Medicine|November 20, 2021
Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?Andre C Kalil, Kelly A Cawcutt
Chest|August 10, 2019
Quick Sequential Organ Failure Assessment Is Not Good for Ruling Sepsis In or OutAndre C Kalil, Flavia R Machado
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 5, 2021
Mortality in solid organ transplant recipients hospitalized for COVID-19Andre C Kalil, Diana F Florescu
Critical Care Medicine|May 25, 2022
From Syphilis to Sepsis: Pilot Studies and the Importance of Staying GroundedDaniel A Sweeney, Andre C Kalil
The Lancet. Infectious Diseases|September 30, 2019
Can ceftolozane-tazobactam treat nosocomial pneumonia?Andre C Kalil, Alexandre P Zavascki
Critical Care (London, England)|December 7, 2018
Didn't inhale? Time to reconsider aerosolized antibiotics in the treatment of ventilator-associated pneumoniaDaniel A Sweeney, Andre C Kalil
Virulence|November 21, 2013
The complex link between influenza and severe sepsisDiana F Florescu, Andre C Kalil
Critical Care (London, England)|July 6, 2013
Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysisAndre C Kalil, Diana F Florescu
Pageof 28